Abstract
Histopathological evaluation of skeletal muscle biopsies relies on subjective, semi-quantitative assessment with no standardized grading system. We developed a four-tissue deep learning segmentation pipeline using Cellpose-SAM for myofiber instance segmentation, a pixel classifier for fat infiltration, and watershed detection for nuclei. We applied this pipeline to 478 H&E whole-slide images from two independent cohorts: HuashanMuscle (n = 79; China; myotonic dystrophy type 1 [DM1], n = 28; limb-girdle muscular dystrophy type R1 [LGMDR1, calpainopathy], n = 12; type R2 [LGMDR2, dysferlinopathy], n = 22; controls, n = 17) and GTEx (n = 399; United States; three-level myopathy spectrum). Thirty-seven unique morphometric features were extracted per sample. Nuclear centralization index (NCI) and fiber size variability coefficient (fiber CV) discriminated myopathy from controls (p = 1.3E-05, rank-biserial r = 0.69; and p = 2.9E-04, r = 0.58, respectively). DM1 showed the highest NCI (median 0.121), consistent with its centronuclear pathology, and NCI correlated with CTG repeat count (Spearman rho = 0.46, p = 0.042, n = 20). In the GTEx cohort, both biomarkers exhibited significant dose-response trends across the myopathy spectrum (Jonckheere-Terpstra p < E-04). The MyoPath Score, a logistic regression composite of seven pathology indicators trained on GTEx, achieved AUC = 0.788 (LOO-CV 0.735) and transferred to the independent HuashanMuscle cohort with AUC = 0.873 without retraining. Segmentation achieved Dice coefficients of 0.92 (myofiber), 0.95 (fat), 0.87 (nucleus), and 0.88 (connective tissue), with intraclass correlation coefficients exceeding 0.88. NCI and fiber CV provide objective, reproducible quantitative biomarkers for skeletal muscle pathology severity assessment with potential as standardized grading criteria and clinical trial endpoints.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Natural Science Foundation of China (82471426), the National Key Research and Development Program of China (2022YFC3501305, 2022YFC3501303), the Shanghai Hospital Development Center Program (SHDC2023CRD007), and the Open Research Fund of Shanghai Key Laboratory of Gene Editing and Cell Therapy for Rare Diseases (gect-2025-Z01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This retrospective, cross-sectional morphometric study analyzed H&E-stained skeletal muscle sections from two independent cohorts. The HuashanMuscle cohort was collected at Huashan Hospital, Fudan University, under institutional review board approval [IRB number 2022-913]. The GTEx cohort was accessed through the Genotype-Tissue Expression Project (dbGaP accession phs000424). All procedures conformed to the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The GTEx data are available through dbGaP (accession phs000424). HuashanMuscle H&E whole-slide images and MyoPath analysis results are available at https://myotoolkit.huashanmuscle.com. The MyoPath analysis pipeline, including the four-tissue segmentation workflow and all analysis scripts, is available at https://github.com/Hirriririir/MyoPath. Additional data is available from the corresponding authors upon reasonable request.
Funder Information Declared
